文献速递膀胱癌与上尿路尿路上皮癌

术前循环肿瘤DNA预测高危非肌层浸润性膀胱癌根治性膀胱切除术后分期升级与复发

Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomy.
PubMed 文献 · J Urol · 2026-03-17

该双中心研究纳入56例高危非肌层浸润性膀胱癌(NMIBC)患者,在根治性膀胱切除(RC)前后进行肿瘤知情ctDNA检测。术前可检测到ctDNA与更差的无复发生存(RFS)、病理分期升级(≥pT2)及淋巴结转移(pN+)显著相关;术后分子残留病灶窗口内可检测ctDNA亦与更差RFS相关。

要点

  • 术前可检测ctDNA者病理升级(≥pT2)比例66.7% vs 13.3%,pN+比例33.3% vs 0%。
  • 术前可检测ctDNA者RFS显著更差(HR=11,95%CI 2.27-53.8,P<.0001)。
  • 术后90天内可检测ctDNA(分子残留病灶)与更差RFS相关(HR=14.1,P<.0001)。

核心结论

  • 高危NMIBC患者RC术前可检测ctDNA与更差RFS、病理分期升级及淋巴结转移相关。
  • 术后分子残留病灶窗口内可检测ctDNA亦与更差RFS相关。

研究设计与样本

  • 双中心分析纳入2021至2023年接受RC的高危NMIBC(cN0M0)患者56例。
  • 在RC前后进行前瞻性连续肿瘤知情ctDNA检测,分子残留病灶窗口定义为RC后初始90天。
  • 中位随访14个月(IQR 6-18),中位年龄67岁(IQR 62-72);45例有术前ctDNA数据。

主要发现

  • 45例术前ctDNA可评估患者中,15例(33.3%)可检测,30例(66.7%)不可检测。
  • 术前可检测ctDNA者病理升级(≥pT2)66.7% vs 13.3%,pN+ 33.3% vs 0%(OR=13.0,95%CI 3.13-66.1,P<.001)。
  • 术前不可检测ctDNA者中20%为pT0,无≥pT3或pN+病变。
  • 术前可检测ctDNA者RFS更差(HR=11,95%CI 2.27-53.8,P<.0001);6个月RFS 64.3%(43.5-95)vs 100%,12个月RFS 38.6%(17.1-87.2)vs 95.7%(87.7-100)。
  • 术后分子残留病灶窗口内可检测ctDNA与更差RFS相关(HR=14.1,95%CI 3.12-63.7,P<.0001)。

临床怎么用

  • 术前ctDNA检测可能辅助识别高危NMIBC中病理升级和淋巴结转移风险较高的患者。
  • 术后90天内ctDNA检测可能用于分子残留病灶评估和复发风险分层。

局限性

  • 样本量较小(56例),随访时间较短(中位14个月)。
  • 仅45例有术前ctDNA数据,部分患者缺乏检测结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to assess if precystectomy circulating tumor DNA (ctDNA) status predicts recurrence-free survival (RFS) and correlates with disease upstaging in patients with high-risk nonmuscle-invasive bladder cancer (NMIBC) undergoing radical cystectomy (RC). MATERIALS AND METHODS: We conducted a bicenter analysis of patients with high-risk NMIBC (cN0M0) who underwent RC between 2021 and 2023 and had prospective serial tumor-informed ctDNA analyses performed before and after RC. The molecular residual disease window was defined as the initial 90 days after RC. The primary end point RFS was analyzed with the Kaplan-Meier method. RESULTS: A total of 56 patients with NMIBC with a median follow-up time of 14 months (IQR 6-18) and a median age of 67 years (IQR 62-72) were included; among them, 45 patients had pre-RC ctDNA available, 15 patients (33.3%) had detectable, and 30 patients (66.7%) had undetectable ctDNA. Twelve patients had bacillus Calmette-Guérin-unresponsive disease (26.8%). The most common pre-RC pathology was T1HG (60%) and T1HG + carcinoma in situ (28.9%). Detectable pre-RC ctDNA cases were more commonly upstaged (≥pT2) 66.7% vs 13.3%, and 33.3% vs 0% had pN+ (odds ratio = 13.0 [3.13-66.1], P < .001). Among patients with undetectable ctDNA, 20% had pT0 and none had ≥ pT3 or pN+ disease. On survival analysis, detectable pre-RC ctDNA had worse RFS than undetectable ctDNA (log-rank, P < .0001, HR = 11 [2.27-53.8]), with worse 6-month RFS of 64.3% (43.5-95) vs 100% and 12-month RFS of 38.6% (17.1-87.2) vs 95.7% (87.7-100), respectively. Detectable molecular residual disease ctDNA was associated with worse RFS than undetectable ctDNA (log-rank, P < .0001, HR = 14.1 [3.12-63.7], P = .001). CONCLUSIONS: Detectable ctDNA for high-risk NMIBC pre-RC was associated with worse RFS, increased risk of pathological upstaging, and locally advanced disease with lymph node metastasis.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ben-David R, Raizenne BL, Eraky A, et al. Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomy. J Urol. 2026. PMID: 41843048. doi:10.1097/JU.0000000000005034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。